Abstract
Parkinson's disease (PD) has become a significant concern for public health due to its disabling nature and high prevalence in the aging population. No cure or disease-modifying drug exists besides the availability of symptomatic medical and surgical treatments, which has led to increased medical costs. To fill this gap, novel therapeutic approaches are investigating new uses for approved drugs. Besides their ability to kill or delay microbial proliferation, antibiotics also have properties effective against disorders where inflammation is a contributing factor to disease progression to PD. Many antibiotics cross the blood–brain barrier and have been used for several decades without severe toxic effects and antimicrobial resistance. Experimental evidence supports their potential as neuroprotective agents that are useful in preventing neuroinflammation, mitochondrial dysfunction, and the formation of toxic alfa-synuclein oligomers. The present chapter carefully brings together evidence concerning the main types of antibiotics used on neurodegenerative diseases, specifically showing their action mechanism on PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
